Clinical trial NCT05565521: UNITy-BasED MR-Linac Adaptive Simultaneous Integrated Hypofractionated Boost Trial for High Grade Glioma in the Elderly
Official title: UNITy-BasED MR-Linac Adaptive Simultaneous Integrated Hypofractionated Boost Trial for High Grade Glioma in the Elderly
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Glioblastoma Multiforme, Adult
Glioblastoma, IDH-mutant
Lead sponsor: Sunnybrook Health Sciences Centre
Sponsor class: OTHER
First posted: 2022-10-04
Enrollment: 55
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The usual standard of care for patients over 65 diagnosed with glioblastoma ("GBM") or Grade 4 astrocytoma, IDH-mutant is a 3-week course of radiotherapy, with concurrent and adjuvant temozolomide (TMZ). This radiation dose and length of treatment are less than what would be given for younger patients, primarily due to unclear survival benefits from randomized trials. However, survival remains dismal, and may be partially due to the reduced radiation dose. Recent studies investigating this have found that increased radiation dose (to the equivalent of what is normally given over 6 weeks in younger patients) over 3 weeks is well-tolerated and has improved survival rates.

Additionally, with the advent of novel technology such as the MR-Linac, adaptive radiotherapy with this regimen using reduced radiation margins is possible. Use of the MR-Linac allows for daily MRI scans to be done prior to treatment, so plans can be adapted to tumour dynamics and anatomical deformations. In this trial, we will examine the outcomes of increased radiation dose, combined with reduced-margin adaptive radiotherapy in this patient population.


Eligibility criteria: Inclusion Criteria:

* Patient age ≥ 65 years
* Histopathologically confirmed, based on biopsy or surgical resection, glioblastoma or WHO grade 4 astrocytoma, IDH-mutant
* Biopsy or surgical resection performed ≤ 6 weeks prior to study entry
* Deemed suitable by the treating physicians for 15 daily fractions of radiation, delivered daily over 3 weeks, with concurrent temozolomide chemotherapy
* Expected survival ≥ 12 weeks
* ECOG performance status of 0, 1 or 2
* Able (sufficiently fluent in English) and willing to complete QOL questionnaires; however, inability to complete the questionnaires will not make the patient ineligible for the study
* Sufficient estimated glomerular filtration rate (eGFR) of ≥ 30 mL/min/1.73 m2 to allow administration of gadolinium-based contrast agent; patients with eGFR \< 30 mL/min/1.73 m2 not on dialysis may be allowed on the study after discussion of risks and benefits and approval by study neuroradiologist(s)
* Completed written informed consent
* Patient must be accessible for treatment and follow-up

Exclusion Criteria:

* Contraindications to MRI as per standard MRI screening policy
* Contraindication to Gadolinium-based contrast media
* Inability to lie flat in a supine position for at least 90 minutes
* Inability to tolerate immobilization in a head thermoplastic mask
* Patients \> 140 kg and/or a circumference \> 60 cm
* Prior dose-limiting cranial irradiation
* T1w post-gadolinium enhancing disease involving the brainstem
* Leptomeningeal dissemination of disease
* Patients with any condition (e.g. psychological, geographical, etc.) that does not permit compliance with the protocol

Primary outcomes:
measure: Progression-free survival at 6 months following chemoradiation
timeFrame: 6 months from study entry date
Secondary outcomes:
measure: Overall survival
timeFrame: Through study completion, an average of 9 months
measure: Progression-free survival
timeFrame: Through study completion, an average of 5 months
measure: Local control
timeFrame: Through study completion, an average of 5 months
measure: Patterns of Failure
timeFrame: Through study completion, an average of 5 months
measure: Toxicity and Health-related Quality of Life Changes based on the EORTC QLQ-C30
timeFrame: Through study completion, an average of 9 months
measure: Toxicity and Health-related Quality of Life Changes based on the EORTC QLQ-BN20
timeFrame: Through study completion, an average of 9 months
measure: Compare differences in adaptive vs non-adaptive with regards to treatment volume
timeFrame: 6-12 months
measure: Compare differences in adaptive vs non-adaptive with regards to organ-at-risk doses
timeFrame: 6-12 months
measure: Compare differences in adaptive vs non-adaptive with regards to cumulative dose
timeFrame: 6-12 months
measure: Compare differences in adaptive vs non-adaptive with regards to length of radiation treatment time
timeFrame: 6-12 months
measure: Functional Imaging Kinetics as a Correlate of Treatment Response
timeFrame: 12-24 months
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: Odette Cancer Centre, Sunnybrook Health Sciences Centre
state: Ontario
Study officials:
References: